COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS

被引：0
|
作者：
Olasupo, O. [1 ]
Matino, D. [1 ]
Iorio, A. [1 ]
Blackhouse, G. [1 ]
Xie, F. [1 ]
Tarride, J. E. [1 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE476
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    BLOOD, 2022, 140 : 13041 - 13042
  • [2] EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS
    Lee, H.
    Cho, H.
    Han, J. W.
    Kim, A.
    Park, S.
    Lee, M.
    Cho, S.
    Baik, D.
    Kang, H. Y.
    VALUE IN HEALTH, 2019, 22 : S849 - S849
  • [3] Emicizumab Prophylaxis in Patients with Hemophilia. with and without Inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    BLOOD, 2019, 134
  • [4] Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors
    Cortesi, Paolo Angelo
    Castaman, Giancarlo
    Trifiro, Gianluca
    Creazzola, Simona Serao
    Improta, Giovanni
    Mazzaglia, Giampiero
    Molinari, Angelo Claudio
    Mantovani, Lorenzo Giovanni
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 216 - 228
  • [5] Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
    Sun, Shawn X.
    Wu, Yanyu
    McDermott, Michael
    van Keep, Marjolijn
    BLOOD, 2019, 134
  • [6] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [7] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
    Cortesi, P. A.
    Castaman, G.
    Trifiro, G.
    Ferrario, M.
    Improta, G.
    Mazzaglia, G.
    Molinari, A. C.
    Mantovani, L. G.
    VALUE IN HEALTH, 2019, 22 : S845 - S845
  • [8] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
  • [9] Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru
    Bitran, Ricardo
    Pena, Camila
    Arpon, Paula
    Loayza, Nancy
    Salas, Katia
    del Villar, Carmen
    Chumpitaz, Gloria
    Salinas, Virgilio
    MEDWAVE, 2022, 22 (02):
  • [10] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
12345